Welcome to our dedicated page for Genmab news (Ticker: GMAB), a resource for investors and traders seeking the latest updates and insights on Genmab stock.
Genmab A/S (GMAB) generates frequent news flow as an international biotechnology company focused on antibody medicines for cancer and other serious diseases. Company announcements highlight advances in its antibody platforms, late‑stage clinical programs, regulatory milestones and corporate transactions, offering investors and observers a detailed view of how its science translates into clinical and commercial progress.
Recent news has emphasized the expanding clinical profile of epcoritamab (EPKINLY), an IgG1‑bispecific antibody created using Genmab’s DuoBody technology. Genmab regularly reports data from Phase 1b/2 and Phase 3 trials in diffuse large B‑cell lymphoma, follicular lymphoma and Richter transformation, including monotherapy and combination regimens with standard treatments such as R‑CHOP, R‑mini‑CHOP, rituximab and lenalidomide, and bendamustine plus rituximab. These updates often include response rates, survival outcomes and safety findings from major oncology congresses.
News coverage also includes developments in Genmab’s wholly owned pipeline, such as updated data for rinatabart sesutecan (Rina‑S) in advanced endometrial cancer and the expansion of its clinical program into Phase 3 trials. Corporate strategy items, including the planned acquisition and subsequent tender offer for Merus N.V. to add petosemtamab to the portfolio, feature prominently in company announcements and SEC‑related communications.
In addition, Genmab reports on initiatives that shape how it conducts research and development, such as its partnership with Anthropic to deploy Claude‑powered agentic AI solutions to support clinical development operations. Visitors to this GMAB news page can review these company announcements, trial readouts, regulatory updates and transaction disclosures to follow how Genmab’s antibody platforms, collaborations and late‑stage assets evolve over time.
Seagen and Genmab submitted a Biologics License Application (BLA) to the FDA for tisotumab vedotin, aimed at treating recurrent or metastatic cervical cancer following chemotherapy. The BLA is based on the innovaTV 204 phase 2 clinical trial, which showed durable responses and a manageable safety profile in patients. Approximately 13,500 women are diagnosed with invasive cervical cancer annually in the U.S., highlighting the need for effective therapies. This milestone could significantly benefit patients with high unmet medical needs.